Pfizer, BioNTech’s Coronavirus Vaccine Effective More Than 90% Effective

Pfizer and Germany’s BioNTech companies announced on Monday that they had found a coronavirus vaccine candidate, which is more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.

In a statement, Pfizer said its study included 43,538 participants, with 42% having perse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected.

"Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine's ability to prevent COVID-19,” Pfizer Chairman and CEO Albert Bourla said.

https://twitter.com/pfizer/status/1325767629890592771

Bourla pointed out: "With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis."

The protection from the virus happens 28 days after the initiation of the vaccination, which consists of a two-dose schedule.

Pfizer and BioNTech expected that they would produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.

"Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November," the statement read.